cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Rivan Danuaji
Contact Email
magnaneurologica@mail.uns.ac.id
Phone
+6282138018361
Journal Mail Official
magnaneurologica@mail.uns.ac.id
Editorial Address
Departement of Neurology, Faculty of Medicine Universitas Sebelas Maret, Surakarta, Indonesia Jl. Kol. Sutarto No. 132 Surakarta, Indonesia
Location
Kota surakarta,
Jawa tengah
INDONESIA
Magna Neurologica
Published by Universitas Sebelas Maret
ISSN : 29636027     EISSN : 29853729     DOI : https://doi.org/10.20961/magnaneurologica.v1i2.647
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health
Magna Neurologica is a peer-reviewed and open access journal that focuses on promoting neurological sciences generated from basic neurosciences and clinical neurology. This journal publishes original articles, reviews, and also interesting case reports. Brief communications containing short features of medicine, latest developments in diagnostic procedures of neurology disease, treatment, or other health issues related to neurology that is important also acceptable. Letters and commentaries of our published articles are welcomed.
Arjuna Subject : Kedokteran - Neurologi Klinis
Articles 15 Documents
 1   2 
Search results for , issue "Vol. 4 No. 1 (2026): January" : 15 Documents clear
Fahr Disease in Elderly Patients with Bronchopneumonia and History of Ischemic Stroke: A Case Report and Literature Review Miftahul Hasanah; Aditya Putra Priyahita
Magna Neurologica Vol. 4 No. 1 (2026): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v4i1.2392

Abstract

Background: Fahr's Disease (Fahr's Syndrome) is a rare condition characterized by idiopathic bilateral basal ganglia calcifications, typically occurring in the lateral parts of the globus pallidus, dentate nuclei, and caudate nuclei. Diagnosis is based on clinical features of neuropsychiatric and somatic symptoms in conjunction with radiological findings. We report an unusual case of Fahr's disease in a 70-year-old woman with bronchopneumonia and a history of chronic ischemic stroke identified through a CT-SCAN. Case: The patient was a 70-year-old female, admitted to our emergency department with bronchopneumonia, who presented with declining consciousness and focal seizures for 3 hours before entering the hospital. Her brain’s CT scan revealed calcification in the bilateral lentiform nuclei, bilateral cerebellar dentate nuclei, and left corona radiata, consistent with Fahr's disease. The patient was also diagnosed with bronchopneumonia and chronic ischemic stroke. Discussion: Fahr's Disease is linked to abnormal calcium metabolism, leading to calcifications in the basal ganglia. While chronic ischemic stroke may not directly cause Fahr's Disease, it increases the risk of cerebrovascular events in affected individuals. The correlation between infection and Fahr's Disease is poorly understood, although it may exacerbate neurological symptoms. Conclusion: Basal ganglia calcification in Fahr's disease may be associated with an increased risk of stroke and bronchopneumonia, which can worsen the patient's condition. Further research is needed to understand the relationship between Fahr's disease, ischemic stroke, and infections.
Cell Based Treatment for Spinocerebellar Ataxia: A Clinical Case Report Damar Dyah Mentari; Rivan Danuaji
Magna Neurologica Vol. 4 No. 1 (2026): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v4i1.2412

Abstract

Background: Spinocerebellar ataxia (SCA) is a dominant and monogenic central nervous system disorder, characterized by progressive motor disorders affecting coordination, balance, speech, and ADL. The prevalence is 2.7 out of 100,000 people. Currently, cell-based therapy is being developed for clinical improvement in SCA. Case: A 48-year-old woman with weakness in both legs and arms, difficulty walking, dysmetria, and dysarthria since 2015. Examination of SARA scoring is severe ataxia, EMG showed polyradiculopathy, muscle denervation, and suspicion of posterior ramus lesions; complete blood laboratory and tumor markers were routine. MRI brain contrast and whole spine contrast radiology imaging were also performed. Clinical improvement was achieved in 2016 following stem cell injection in Thailand (dose and type of cells unknown). However, clinical worsening occurred from 2020 to 2024. The patient received Umbilical Cord Mesenchymal Stem Cells (MSC) in October 2024, administered intrathecally at a dose of 20 million cells. Discussion: The first injection showed significant clinical improvement. The second injection showed no clinical improvement, but no worsening of symptoms was found. The difference in results may be due to variations in the route of administration, cell type, cell quality, and the dose administered. Conclusion: The administration of umbilical cord mesenchymal stem cells (UC-MSCs) in SCA is considered safe, with minimal complications, and can suppress disease progression, although it does not produce clinical improvement.
Vitamin D Receptor Gene Polymorphisms in Multiple Sclerosis Susceptibility: Updated Systematic Review and Meta-Analysis Han Yang; Baarid Luqman Hamidi; Esti Nur Ekasari; Krisandi Hartanto; Rudi Ilhamsyah
Magna Neurologica Vol. 4 No. 1 (2026): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v4i1.2417

Abstract

Background: The relationship between Vitamin D Receptor (VDR) gene polymorphisms and the risk of developing Multiple Sclerosis (MS) has been explored in numerous studies. However, the results were inconclusive. Therefore, this study aimed to investigate the relationship between VDR gene polymorphisms and susceptibility to MS. Objective: This study aimed to systematically evaluate the association between Vitamin D Receptor (VDR) gene polymorphisms and susceptibility to Multiple Sclerosis (MS) through a meta-analysis of existing studies. Methods: This study is a meta-analysis conducted in accordance with the PRISMA guideline. The literature search was conducted using the PubMed and Google Scholar databases from January 2014 to December 2024. Studies included in this meta-analysis were assessed using the Newcastle-Ottawa Scale (NOS). The association between VDR polymorphisms and the risk of MS was evaluated using pooled odds ratios (ORs) and 95% confidence intervals (CIs). Results: Six studies (868 cases/982 controls) were included. The TaqI polymorphism showed that TT vs TC + CC was associated with reduced risk of MS (OR 95% CI = 0.43 [0.21 - 0.86], p = 0.02), while CC vs TT + TC was associated with an increased risk of MS (OR 95% CI = 1.89 [1.51 - 2.36], p < 0.00001). T vs C was associated with reduced risk of MS (OR 95% CI = 0.69 [0.49 - 0.98], p = 0.04) while C vs T was associated with an increased risk of MS (OR 95% CI = 1.45 [1.02 – 2.05], p < 0.04). Conclusion: In summary, our meta-analysis revealed a significant association between VDR gene polymorphism and MS susceptibility in certain genetic models of the VDR gene.
Oligodendrocyte Differentiation from Human iPSCs: Strategies Based on Signaling Pathways, Transcription Factors, and Novel Modulators for Research and Therapy Maria Maylyn Evangelina Wong; Michelle Angelica Subrata
Magna Neurologica Vol. 4 No. 1 (2026): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v4i1.2601

Abstract

Background: Oligodendrocytes (OLs) are vital for central nervous system (CNS) function, producing myelin sheaths and maintaining axonal integrity. However, their limited accessibility in human disease-relevant contexts has historically hindered progress in research. The advent of induced pluripotent stem cell (iPSC)-derived OLs has transformed the study of myelin-related diseases and regenerative therapies. Objective: This review aims to provide a comparative overview of strategies for generating OLs from human iPSCs, emphasizing their mechanisms, efficiency, scalability, and translational applications. Methods: We analyzed three major differentiation approaches described in recent literature. Signaling-based protocols replicate developmental processes by modulating TGF-β, SHH, and Wnt pathways. Transcription factor-driven methods accelerate lineage specification by directly inducing OL fate. Modulator-enhanced strategies incorporate epigenetic, metabolic, or environmental cues to improve efficiency and adaptability. Results: Each approach offers distinct strengths and limitations. Signaling-based methods closely mimic in vivo development but require long culture times. Transcription factor-driven strategies enable rapid OL generation, although sometimes at the expense of physiological relevance. Modulator-enhanced protocols represent an emerging avenue, offering flexibility and potential for higher efficiency. Collectively, these strategies expand opportunities for disease modeling, therapeutic screening, and cell replacement therapies. Conclusion: Advances across signaling, transcriptional, and modulatory domains have significantly advanced iPSC-based OL generation. Integration of these approaches may enable more efficient, scalable, and physiologically relevant OL production. Such progress holds significant potential to accelerate the development of myelin targeted therapeutics and enhance translational research in demyelinating diseases.
Acute Malignant Transformation as A Rare Complication of Middle Cerebral Artery Infarction Annisa Bunga Nafara; Ika Yulieta Margaretha Permatasari
Magna Neurologica Vol. 4 No. 1 (2026): January
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v4i1.2644

Abstract

Background: Malignant ischemic stroke is a stroke characterized by extensive acute edema resulting in a space-occupying lesion. This transformation occurs in 10% of ischemic strokes with a mortality rate up to 80%. Hence, it is crucial to early detection and timely treatment. Case: A 51-year-old male was diagnosed with ischemic stroke, presented with NIHSS 11 and ASPECTS 4. Within 26 hours, the patient's level of consciousness declined progressively from a GCS of 15 to a GCS of 10. Serial brain imaging using CT scan and MRI revealed infarct expansion, a space-occupying lesion, and further midline shift. During decompressive craniectomy, extensive edema was found without hemorrhage, suggesting malignant ischemic stroke. After 6 months, the patient had undergone cranioplasty, with no significant complaints, but left hemiparesis remained. Discussion: Malignant ischemic stroke occurs within 5 days after onset. Diagnosis of malignant complication should be considered in ischemic stroke patients with younger age, higher NIHSS, not receiving thrombolysis, neurological status decline in 4-6 hours after onset, wide hypoattenuation in MCA territory, and signs of progressive space-occupying lesion in brain imaging. Management of malignant ischemic stroke consists of managing intracranial pressure with pharmacology and decompressive craniectomy. Conclusion: Malignant transformation is a rare complication of ischemic stroke. Early and accurate diagnosis is crucial to determine the prognosis. Pharmacological therapy and decompressive craniectomy surgery are considered life-saving therapies, but are not able to reduce morbidity in the patient.

Page 2 of 2 | Total Record : 15

 1   2 

Filter by Year

2026 2026


Reset
Filter By Issues
All Issue Vol. 4 No. 1 (2026): January Vol. 3 No. 2 (2025): July Vol. 3 No. 1 (2025): January Vol. 2 No. 2 (2024): July Vol. 2 No. 1 (2024): January Vol. 1 No. 2 (2023): July Vol. 1 No. 1 (2023): January